Critical Review: Q32 Bio (NASDAQ:QTTB) versus Genelux (NASDAQ:GNLX)

Genelux (NASDAQ:GNLX – Get Free Report) and Q32 Bio (NASDAQ:QTTB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Risk and Volatility

Genelux has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Insider & Institutional Ownership

37.3% of Genelux shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Genelux and Q32 Bio”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genelux $10,000.00 8,686.08 -$32.15 million ($0.86) -2.23
Q32 Bio $53.74 million 4.62 $29.82 million $3.34 2.48

Q32 Bio has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Genelux and Q32 Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genelux N/A -205.85% -138.79%
Q32 Bio N/A 17.03% 15.24%

Analyst Recommendations

This is a summary of recent ratings for Genelux and Q32 Bio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux 1 0 2 1 2.75
Q32 Bio 1 1 6 1 2.78

Genelux presently has a consensus price target of $20.00, indicating a potential upside of 941.67%. Q32 Bio has a consensus price target of $32.17, indicating a potential upside of 288.02%. Given Genelux’s higher probable upside, research analysts clearly believe Genelux is more favorable than Q32 Bio.

Summary

Q32 Bio beats Genelux on 9 of the 13 factors compared between the two stocks.

About Genelux

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

About Q32 Bio

(Get Free Report)

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.